ATE109351T1 - Therapeutisches erzeugnis zur behandlung von beschwerden während der oder nach den wechseljahren. - Google Patents

Therapeutisches erzeugnis zur behandlung von beschwerden während der oder nach den wechseljahren.

Info

Publication number
ATE109351T1
ATE109351T1 AT89305563T AT89305563T ATE109351T1 AT E109351 T1 ATE109351 T1 AT E109351T1 AT 89305563 T AT89305563 T AT 89305563T AT 89305563 T AT89305563 T AT 89305563T AT E109351 T1 ATE109351 T1 AT E109351T1
Authority
AT
Austria
Prior art keywords
menopause
treatment
therapeutic product
product
oestrogen
Prior art date
Application number
AT89305563T
Other languages
English (en)
Inventor
Michael Dukes
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE109351T1 publication Critical patent/ATE109351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89305563T 1988-06-06 1989-06-02 Therapeutisches erzeugnis zur behandlung von beschwerden während der oder nach den wechseljahren. ATE109351T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888813353A GB8813353D0 (en) 1988-06-06 1988-06-06 Therapeutic product

Publications (1)

Publication Number Publication Date
ATE109351T1 true ATE109351T1 (de) 1994-08-15

Family

ID=10638154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89305563T ATE109351T1 (de) 1988-06-06 1989-06-02 Therapeutisches erzeugnis zur behandlung von beschwerden während der oder nach den wechseljahren.

Country Status (17)

Country Link
US (1) US5183814A (de)
EP (1) EP0346014B1 (de)
JP (1) JP2918042B2 (de)
AT (1) ATE109351T1 (de)
AU (1) AU622184B2 (de)
CA (1) CA1337591C (de)
DE (1) DE68917219T2 (de)
DK (1) DK175740B1 (de)
ES (1) ES2057124T3 (de)
FI (1) FI892762A7 (de)
GB (1) GB8813353D0 (de)
IE (1) IE64368B1 (de)
IL (1) IL90410A (de)
NO (1) NO892293L (de)
NZ (1) NZ229392A (de)
PT (1) PT90764B (de)
ZA (1) ZA893892B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19510862A1 (de) * 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5965551A (en) * 1996-02-21 1999-10-12 North Carolina State University Method of treating alopecia
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
EP1287817A1 (de) * 2001-08-31 2003-03-05 Pantarhei Bioscience B.V. Verfahren und intravaginales Arzneiverabreichungsvorrichtung zur Behandlung von uterinem Myom
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
SK622004A3 (en) 2001-07-31 2004-08-03 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
EP1622623A4 (de) * 2003-04-11 2009-03-18 Barr Lab Inc Verfahren zur verabreichung von östrogenen und gestagenen
CN1867341B (zh) * 2003-10-17 2010-06-16 英特威国际有限公司 用于控制寄生虫的包括阿巴克丁与伊维菌素的组合的组合物
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
JP2009509942A (ja) * 2005-09-26 2009-03-12 ホスピラ・オーストラリア・ピーティーワイ・リミテッド フルベストラント製剤
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
EP2258375A1 (de) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratriene
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
AU3592389A (en) 1989-12-07
FI892762L (fi) 1989-12-07
IL90410A (en) 1994-07-31
JPH0242024A (ja) 1990-02-13
JP2918042B2 (ja) 1999-07-12
PT90764B (pt) 1994-10-31
DE68917219T2 (de) 1994-12-15
GB8813353D0 (en) 1988-07-13
US5183814A (en) 1993-02-02
NO892293D0 (no) 1989-06-05
DK273489D0 (da) 1989-06-02
EP0346014B1 (de) 1994-08-03
CA1337591C (en) 1995-11-21
IE64368B1 (en) 1995-07-26
FI892762A7 (fi) 1989-12-07
NZ229392A (en) 1992-01-29
ZA893892B (en) 1990-02-28
PT90764A (pt) 1989-12-29
FI892762A0 (fi) 1989-06-06
DK175740B1 (da) 2005-02-07
DE68917219D1 (de) 1994-09-08
DK273489A (da) 1989-12-07
NO892293L (no) 1989-12-07
EP0346014A1 (de) 1989-12-13
AU622184B2 (en) 1992-04-02
ES2057124T3 (es) 1994-10-16
IE891670L (en) 1989-12-06

Similar Documents

Publication Publication Date Title
ATE109351T1 (de) Therapeutisches erzeugnis zur behandlung von beschwerden während der oder nach den wechseljahren.
ATE30575T1 (de) Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten.
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3070189D1 (en) Medicament, particularly for the treatment of cholera, and pharmaceutical compositions containing it
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
ES8503643A1 (es) Un procedimiento para la preparacion de compuestos de bis (carboxamida)
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
EP0295695A3 (en) New pyrazoline derivatives and agents for treating cerebnew pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredrovascular diseases containing the same as active ingredient ient
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
IE45054L (en) Veterinary composition
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
FR2614203B1 (fr) Composition pharmaceutique pour le traitement des maladies de la peau et son procede de preparation.
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE263573T1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
FR2355508B1 (fr) Medicament destine a la prevention et au traitement des caries dentaires et des parodontopathies et son procede de preparation
Campbell et al. Psychotherapy and chronic hemodialysis.
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
JPS527416A (en) Process for extracting blood clotting 3 factor of staphylococcus aureu s
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time